Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESTINY-Lung06: T-DXd + pembrolizumab vs platinum-pemetrexed + pembrolizumab in first-line HER2-overexpressing NSCLC
jRCT2071250040Phase 3Recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Sep 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 3, randomised, open-label trial of trastuzumab deruxtecan and pembrolizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Progression-free survival by BICR (primary). Started Sep 2025; status: recruiting.
02
Drugs
trastuzumab deruxtecanpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2071250040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071250040.